• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Investments

Deal in focus: IK sells Vemedia to Charterhouse Capital

Deal in focus: IK sells Vemedia to Charterhouse Capital
  • Alice Tchernookova
  • Alice Tchernookova
  • 04 August 2016
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

IK Investment Partners recently exited pharmaceutical company Vemedia in a secondary buyout to Charterhouse Capital Partners. Alice Tchernookova investigates how the vendor helped the group grow from a Benelux-focused business into a pan-European player

The sale, which according to information published on Vemedia's website was worth €375m, was completely very rapidly, with no competing bids and no auction process.

"Once Charterhouse had completed the acquisition of Cooper in early 2016, they approached us almost immediately," says partner Remko Hilhorst, in charge of the deal at IK. "We agreed on a price, and we did the deal."

International law firm Allen & Overy acted as IK's legal adviser on the transaction, with no corporate finance or M&A advice solicited. The seller made more than 2x money on the exit, a source close to the deal told unquote".

At the time of acquisition by IK in 2012, Vemedia was a Belgium-based company headquartered in in the Flemish province of Kortrijk, and operated in the Benelux region only. IK's ambition as it entered the group was to transform it into a global player, applying a buy-and-build strategy.

We had to take it private as having many shareholders in the group would have complicated things significantly, and would have impeded on the implementation of our strategy" - Remko Hilhorst, IK Investment Partners

When the GP acquired a majority stake from founder and CEO Yvan Vindevogel, the business was a listed entity. "We had to take it private as having many shareholders in the group would have complicated things significantly, and would have impeded on the implementation of our strategy," explains Hilhorst.

He adds: "The owner at the time was looking for a strong partner to continue the group's consolidation in the industry; the business was listed with Mr Vindevogel as controlling shareholder, and it had become hard for Vemedia to raise substantial additional capital to make further acquisitions."

At the time of investment, the owner had diluted himself to around 55%, unquote" understands. A subsequent acquisition would have consequently resulted in a further reduction of his stake in the group, and to a consequent loss of control over the business.

This is how in 2012, Vindevogel decided for the first time to turn to a private equity fund, deeming it a better option to have one single majority shareholder to manage the group rather than a few minority ones.

Building for the future
With IK's backing, Vemedia Pharma doubled in size with revenues reaching the €150m mark last year, compared to €75m in 2012. Early on, the GP had identified target companies for bolt-on acquisitions that would help it grow into a European OTC drugs platform.

IK first bolted-on Excilor, a Belgian company specialised in medical foot care. The GP further made a significant push in the French market with six acquisitions, the most significant of which was beauty nutritional supplement specialist Oenobiol, previously owned by Sanofi. Other investments included consumer healthcare group Stardea in Italy, bolted on in February this year, as well as Belgium-based Labima in June 2015.

As the new majority shareholder, alongside the CEO and management who retain a minority stake in the group, Charterhouse Capital is merging French portfolio company Cooper with Vemedia. The new entity should generate €400m of sales and a €100m EBITDA, with a 790 headcount and operations in 45 countries, directly and through third parties.

We had been in the business for three-and-a-half years; the next step had to be a significant acquisition like Cooper, but this was too big a deal for us, so it was best to pass it on to the next owner" - Remko Hilhorst, IK Investment Partners

"It's a very logical move from an industry perspective. It makes sense to put those businesses together," says Hilhorst, pointing to the fact that Cooper will highly benefit from Vemedia's European presence.

From IK's perspective, the time had come to make a move, the partner explains: "We had been in the business for three-and-a-half years; the next step had to be a significant acquisition like Cooper, but this was too big a deal for us, so it was best to pass it on to the next owner - a slightly bigger fund."

Charterhouse now wants to take the next step in Cooper's development, planning to grow it on an international scale. The new investor said it would work with both management teams over the coming months to identify consolidation opportunities.

Simultaneously with the sale, the group announced the acquisition of Vision Healthcare - a €10m Netherlands-based healthcare company made up of five brands. Other bolt-on acquisitions should soon follow up.

People
IK Investment Partners - Remko Hilhorst (partner); Frederik Jacobs (associate).

Advisers
Vendor - Allen & Overy (legal).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Investments
  • Benelux
  • Healthcare
  • Deal in focus
  • Top story
  • Belgium
  • Secondary buyout
  • IK Investment Partners
  • Charterhouse Capital Partners

More on Investments

Change of mind: Sponsors take to de-listing their own assets
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • Investments
  • 01 September 2023
Evoco expects portfolio acquisitions, assesses potential exits in 2H23
Evoco expects portfolio acquisitions, assesses potential exits in 2H23

Switzerland-headquartered GP is currently deploying equity via its EUR 162m Evoco TSE III fund

  • Investments
  • 21 August 2023
Turning the tables – an M&A downturn means investment banks are now targets themselves
Turning the tables – an M&A downturn means investment banks are now targets themselves

Some dealmakers with healthy balance sheets and willingness to go countercyclical are pursing acquisitions

  • Investments
  • 14 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013